Pride, prejudice and... PrEP
•Als PPT, PDF herunterladen•
1 gefällt mir•346 views
Appraising the impact of new prevention technologies. This presentation was given by Dean Murphy (AFAO) at the AFAO HIV Educators Conference 2010.
![Background ,[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Andere mochten auch
Andere mochten auch (13)
Ähnlich wie Pride, prejudice and... PrEP
Ähnlich wie Pride, prejudice and... PrEP (20)
Mehr von Australian Federation of AIDS Organisations
Mehr von Australian Federation of AIDS Organisations (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
Pride, prejudice and... PrEP
- 1. Pride, prejudice and... PrEP : appraising the impact of new prevention technologies Dean Murphy AFAO HIV Educators’ Conference 2010 Australian Federation of AIDS Organisations
- 3. Current PrEP trials: when
- 4. Current PrEP trials: what; who
- 5. Current PrEP trials: where
Hinweis der Redaktion
- By the end of 2010 several studies on HIV pre-exposure prophylaxis (PrEP)—including two phase III trials—are scheduled to have concluded and/or have released results. In this presentation I will just cover three things: 1) The when of PrEP. What is on the horizon. Also really briefly the what, who and where of current PrEP clinical. [which ARVs are being tested as potential prophylaxis against HIV infection, in which combination, and the particular dosing strategies; who is enrolled the current trials, meaning the primary HIV risk behaviours of the trial populations; and 4) where the trials are taking place.] 2) A reminder of some of the associations with HIV-related stigma among gay and other MSM in Australia from John de Wit’s presentation yesterday. 3) Some speculation on the impact of PrEP. That’s is, how might PrEP increase, or even decrease, stigma and discrimination. This speculation is based on some of the experience of PrEP clinical trials and the introduction of other prevention technologies, conversations with other working in the field, and the approach that PrEP is not a stable object that will do the same thing in all the environments in which it is introduced. Its effects might rather be quite different. So, key questions are: how might the way PrEP interact with existing technologies to add to or reduce stigma? How might existing stigma affect what PrEP will look like in Australia?
- This slide from a site formerly called PrEP watch which is jointly produced by the AIDS Vaccine Advocacy Coalition (AVAC) and UCLA shows the ongoing PrEP trials.
- The second last column in the table shows the intervention arms of the current trials. The first candidate for PrEP is tenofovir on its own which you can see is being used in the first two trials at the top. However as you move down the column you can see (in the boxes with underlining) a number of trials are assessing Truvada (that is tenofovir in combination with FTC) as PrEP. The iPrEX trial of tenofovir and FTC which is due to release results in 2011 is the first phase III study to use a tenofovir/FTC combination rather than tenofovir alone, and is also the first phase III trial among MSM . Two studies are also looking at tenofovir as a topical microbicide.